Uvax Bio

Executive Summary

Uvax Bio is a US-based biotechnology company founded in 2018 and headquartered in Durham, North Carolina. The company is dedicated to developing novel vaccines against infectious diseases leveraging its proprietary 1c-SApNP® protein nanoparticle platform. This platform enables the creation of stable, virus-like particle vaccines designed to elicit potent and broad immune responses, addressing unmet public health needs. Uvax Bio is currently in Phase 1 clinical development, with its lead candidate targeting a significant infectious disease. The company's platform technology has the potential to be applied to multiple pathogens, offering versatility and scalability. As a private company, Uvax Bio is positioned to advance its pipeline through clinical trials and seek strategic partnerships. The upcoming catalysts include data readouts from ongoing Phase 1 studies, which will be critical for demonstrating proof-of-concept and informing the design of subsequent trials. With a strong scientific foundation and a focus on high-impact diseases, Uvax Bio represents an early-stage investment opportunity in the vaccine space.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 interim data readout for lead vaccine candidate60% success
• Q4 2026Initiation of Phase 2 trial for lead candidate40% success
• Q4 2026Potential strategic partnership or licensing deal30% success